<DOC>
	<DOCNO>NCT00081770</DOCNO>
	<brief_summary>The objective compare safety efficacy follow three treatment regimens previously untreated adult subject chronic hepatitis C infect Genotype 1 : ( 1 ) PegIntron 1.5 µg/kg/wk combination weight base REBETOL ( 800-1400 mg/day ) ; ( 2 ) PegIntron 1µg/kg/wk combination weight base REBETOL ( 800-1400 mg/day ) ; ( 3 ) PEGASYS 180 µg/wk plus COPEGUS 1000-1200 mg/day .</brief_summary>
	<brief_title>Peginterferon Dose Evaluations Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 ( Study P03471 )</brief_title>
	<detailed_description>PegIntron Dose administer weekly subcutaneously day week : Screening 2 Weight 40-50 kg Volume Inject ( mL ) 0.22 ; Screening 2 Weight 51-60 kg Volume Inject ( mL ) 0.28 ; Screening 2 Weight 61-75 kg Volume Inject ( mL ) 0.33 ; Screening 2 Weight 76-85 kg Volume Inject ( mL ) 0.41 ; Screening 2 Weight 86-104 kg Volume Inject ( mL ) 0.48 ; Screening 2 Weight 105-125 kg Volume Inject ( mL ) 0.58 two vial REBETOL Dosage ( Use With PegIntron ) : Screening 2 Weight 40-65 kg Daily Dose 800 mg ; Screening 2 Weight &gt; 65-85 kg Daily Dose 1000 mg ; Screening 2 Weight &gt; 85-105 kg Daily Dose 1200 mg ; Screening 2 Weight &gt; 105-125 kg Daily Dose 1400 mg The PEGASYS dose 1 mL ( 180 µg ) administer weekly subcutaneously day week COPEGUS Dosage ( Use With PEGASYS ) : Screening 2 Weight &lt; 75 kg Daily Dose 1000 mg ; Screening 2 Weight &gt; = 75 kg Daily Dose 1200mg NOTE : Double Blind PegIntron ; Open Label REBETOL , PEGASYS COPEGUS NOTE : REBETOL Schering-Plough brand name ribavirin . COPEGUS Hoffman-La Roche brand name ribavirin .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>INCLUSION CRITERIA : Previously untreated adult chronic hepatitis C ( hepatitis C virus ribonucleic acid [ HCV RNA ] quantitative polymerase chain reaction [ qPCR ] plasma positive ) Individuals HCV genotype 1 ( mixed 1a/1b acceptable ) Compensated liver disease Pretreatment liver biopsy slide available Adults age 1870 Individuals weigh 88275 pound ( 40125 kg ) Free substance abuse past 2 year Those suffer diabetes and/or hypertension must normal eye exams retinal photograph ( do part study hepatitis C treatment give ) Patients partner patient willing use adequate contraception course study Hematology laboratory result : Hemoglobin ( HGB ) ≥ 12 g/dL female ≥ 13g/dL male White Blood Cell Count ( WBC ) ≥ 3,000/mm^3 Neutrophils ≥ 1,500/mm^3 Platelets ≥ 80,000/mm^3 Chemistry laboratory result : Normal Thyroid Stimulating Hormone ( TSH ) , albumin , creatinine , direct bilirubin Antinuclear antibody ( ANA ) ≤ 1:320 Fasting Glucose 70140 mg/dL Note : If glucose level 116140 mg/dL individual diabetes , glycosylated hemoglobin [ HbA1C ] must ≤ 8.5 % EXCLUSION CRITERIA : Previous hepatitis C treatment Pregnant woman partner pregnant woman Patients partner patient intend become pregnant time 48 week Women breastfeed Individuals liver disease cause hepatitis C Individuals infect hepatitis B virus and/or human immunodeficiency virus ( HIV ) Patients history liver cancer ( hepatocellular carcinoma ) Known blood disorder hemoglobinopathy , coagulopathy , glucose6phosphate dehydrogenase [ G6PD ] deficiency Body organ transplant Any known suspect cancer within past 5 year Individuals currently use epoetin [ EPO ] , granulocyte colony stimulate factor [ GCSF ] and/or granulocyte monocyte colony stimulate factor [ GMCSF ] Those history active clinical gout Individuals chronic pulmonary disease Individuals medical condition would likely require systemic steroid Those history central nervous system ( CNS trauma ) seizure disorder Current previous use lithium antipsychotic drug Individuals currently show sign moderate severe depression history significant psychiatric disorder Patients clinically significant electrocardiogram ( ECG ) abnormalities Individuals serious heart problem heart attack , uncontrolled high blood pressure , heart problem Patients weigh &gt; 231275 pound ( 105125 kg ) AND body mass index ( BMI ) &gt; 30 AND 3 risk factor : ( ) Strong family history coronary heart disease ( CHD ) include 2 firstdegree relative CHD family history early CHD age &lt; 55 male relative &lt; 65 female relative ( b ) Individuals abnormal total cholesterol and/or sub fraction ( uncontrolled hypercholesterolemia ) ( c ) Diabetes ( ) Hypertension ( e ) Smoking</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>